Microdosing Tirzepatide Chart: The Unit Math Behind the Trend (2026)
Searching for a microdosing tirzepatide chart turns up tables that promise exact numbers for every week of a plan. Most stitch two things together: a dosing schedule and a unit-conversion table. This page covers only the second one.
The Compound Universe Take: A microdosing tirzepatide chart is really a unit-conversion reference, not a dosing schedule. Once a compounded vial is mixed to a known concentration in mg per mL, any milligram amount converts to syringe units with one formula, covered below along with what “microdosing” means and what evidence exists for it. It does not say what amount to use, or whether microdosing makes sense; that call belongs to a licensed prescriber.
Read this before the numbers: This page explains unit math and terminology for educational purposes only. It is not medical or dosing advice, and not a titration protocol. Compounded GLP-1 medicines, including tirzepatide, are tightly restricted as of July 2026 (see the status section below); any actual dose must come from a licensed prescriber or pharmacist, not a chart found online.
Want the numbers run for you? Compound Universe’s unit-conversion calculator applies this math once a concentration is entered.
What a microdosing tirzepatide chart actually means
Microdosing means using an amount below the lowest FDA-approved dose, 2.5 mg once weekly for Zepbound. It describes a behavior, not a clinical term with a fixed schedule. Titration, the gradual dose adjustment a prescriber manages, is a related but separate decision this page does not cover.
Tirzepatide is an FDA-approved medicine (Zepbound, Mounjaro), not a research peptide with uncertain status. What follows concerns compounded copies and self-directed use below that approved floor.
| Vial label | Bacteriostatic water added | Resulting concentration | Conversion rate (1 mg in U-100 units) |
|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 1 mg = 20 units |
| 5 mg | 2 mL | 2.5 mg/mL | 1 mg = 40 units |
| 10 mg | 2 mL | 5 mg/mL | 1 mg = 20 units |
Multiply any other amount by the rate in the last column. These are worked examples only; the vial size and water volume that matter are whatever a pharmacy’s actual label says, not a number picked from a chart.
The mg-to-units formula, briefly
A standard U-100 insulin syringe is calibrated so 100 units equals exactly 1 mL, meaning one unit equals 0.01 mL [1]. Concentration after reconstitution is total peptide mass divided by the liquid it was dissolved in. Combine the two: units = (milligram amount / concentration in mg per mL) x 100. Change the concentration and the answer changes, even though the mg amount never moved, which is why a chart copied from someone else’s vial can be wrong for a different one.
Regulatory: this is not a hypothetical risk. The FDA has logged reports of patients self-administering five to 20 times their intended dose of compounded semaglutide, a related GLP-1 medicine, after confusing milligrams, milliliters, and units, with some errors requiring hospitalization [2]. The failure point is almost always a mismatched concentration, a gap no chart pulled from social media can close.
Microdosing tirzepatide: what the term means and what the evidence shows
Human (survey, not a trial): A 2026 survey of more than 8,000 GLP-1 users found 15 percent had tried microdosing, and close to half did not tell a doctor [4]. That documents a behavior, not proof it works. Cited reasons are lower cost and hope for fewer side effects, though one endocrinologist noted side effects tend to return once the dose rises again [4].
Human (RCT): Tirzepatide’s efficacy data comes from trials at the approved dose range, not below it. In SURMOUNT-1, participants on higher approved doses lost roughly 19 to 21 percent of body weight over 72 weeks, versus about 3 percent on placebo [5]. No randomized trial has tested doses below the approved floor.
Preclinical + human proof-of-concept: Tirzepatide activates both GIP and GLP-1 receptors, a dual mechanism characterized in early discovery and phase 1 work [6]; see Compound Universe’s tirzepatide mechanism and trial summary for the fuller breakdown.
Is compounded tirzepatide legal right now (as of July 2026)
Short version: mass-produced copies of tirzepatide are not a legal substitute for the approved drug, and the room to compound it keeps narrowing.
Regulatory: Tirzepatide left the FDA’s shortage list on October 2, 2024, starting the clock on ending shortage-based compounding [7]. The FDA gave 503A pharmacies until February 18, 2025, and 503B facilities until March 19, 2025, to stop; semaglutide’s shortage ended separately on February 21, 2025 [7][8]. Past those dates, only narrow patient-specific compounding has a legal basis; wanting a cheaper amount is not one.
Regulatory: On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing insufficient clinical need; the comment window, originally set to close in late June 2026, was extended and remains open through July 30, 2026, with a final rule still pending [3]. The agency also sent 2026 warning letters to telehealth sellers over compounded GLP-1 marketing, 30 posted March 3 and 25 more on June 16 [9]. None of this makes any compounded product “legal again”; it narrows an already limited exception. See Compound Universe’s notes on how compounding rules apply across peptides.
| Topic | What is established | Evidence tier | Regulatory status |
|---|---|---|---|
| Tirzepatide at approved doses | Substantial weight loss in trials | Human (RCT) | FDA-approved (Zepbound, Mounjaro) |
| Microdosing (below 2.5 mg) | No controlled trials; self-reported use only | Human (survey only) | Not an approved regimen |
| Mg-to-units conversion errors | FDA-logged reports tied to unit confusion | Regulatory (safety alert) | Active safety concern |
| Compounded tirzepatide (bulk) | Shortage-based compounding window closed | Regulatory | Narrow exception only; bulk exclusion proposed |
Key takeaways
- A microdosing tirzepatide chart is a unit-conversion reference, not a dosing schedule; the amount comes from a licensed prescriber.
- The conversion rate depends on concentration, since a U-100 syringe reads units in 0.01 mL steps, not milligrams directly [1].
- About 15 percent of surveyed GLP-1 users report trying microdosing, but no randomized trial has tested doses below the approved floor [4][5].
- Mismatched concentration assumptions are a documented FDA root cause of compounded GLP-1 overdose reports [2].
- Compounded tirzepatide sits in a narrowing legal lane as of July 2026, with a proposed rule that would end bulk 503B compounding [3][7].
Frequently asked questions
What is a microdosing tirzepatide chart?
Usually a table blending two things: how much to use below the standard dose, and how that converts to syringe units. This page covers only the conversion part; the amount is a medical decision.
Is microdosing tirzepatide safe or effective?
No randomized trial has tested doses below the approved 2.5 mg floor, so effectiveness is unproven. Mainstream coverage quotes an endocrinologist calling it not recommended, since side effects can return once the dose rises again [4].
What counts as a “microdose” of tirzepatide?
Generally, any self-directed amount below Zepbound’s 2.5 mg starting dose, outside any approved protocol.
Why do people try microdosing instead of the standard dose?
Reported reasons are mostly cost and hope for fewer side effects, per survey data rather than trials [4]; neither has been tested against the approved dose.
How do you convert a tirzepatide amount to syringe units?
Divide the milligram amount by the concentration in mg per mL, then multiply by 100 for a U-100 syringe. The result changes whenever concentration changes, which is why the formula matters more than any chart number [1].
Is compounded tirzepatide legal right now?
As of July 2026, only narrow patient-specific compounding is allowed, and a proposed FDA rule would close the bulk pathway too [3][7].
A microdosing tirzepatide chart sits where pharmacy math meets a fast-moving GLP-1 trend: tirzepatide’s dual GIP and GLP-1 receptor mechanism drives the weight-loss data behind Zepbound and Mounjaro at approved doses, reconstitution turns a lyophilized vial into a fixed mg-per-mL concentration, and a U-100 syringe measures that concentration in units. Layered on top is a self-directed microdosing trend a real-world survey puts near 15 percent of GLP-1 users, running ahead of randomized evidence through a compounding channel 503A and 503B rules keep narrowing. Compound Universe tracks the arithmetic, the trend data, and the regulatory calendar as separate threads.
Strip away the marketing and a microdosing tirzepatide chart is useful for one thing: turning a milligram amount someone else has set into a number of syringe units, while the microdosing idea itself still has no trial evidence behind it. The formula is fixed; the concentration it depends on, and whether a lower dose is a good idea, are not. Get the actual amount, and whether tirzepatide is appropriate, from a licensed prescriber or pharmacist, not a chart.
References
- NCBI, StatPearls. Insulin. Bookshelf ID NBK560688 (U-100 = 100 units/mL; basis for syringe-unit conversion).
- FDA. Dosing Errors Associated with Compounded Injectable Semaglutide Products. Late July 2024.
- FDA. Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, Apr 30, 2026; Federal Register, May 1, 2026, Docket 2026-08552 (comment period extended to Jul 30, 2026; Federal Register, Jun 26, 2026, Docket 2026-12937).
- Hackensack Meridian Health. Is Microdosing GLP-1s Safe?, citing ISPOR 2026 real-world survey data on microdosing prevalence. May 12, 2026.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID 35658024.
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14. PMID 30473097.
- FDA. Declaratory Order: Resolution of Shortage of Tirzepatide Injection Products (shortage removal Oct 2, 2024; order Dec 19, 2024; 503A/503B grace periods to Feb 18 and Mar 19, 2025). fda.gov/media/185577/download.
- FDA. Declaratory Order: Resolution of Shortage of Semaglutide Injection Products. Feb 21, 2025.
- FDA. Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s, Mar 3, 2026; follow-on 25-letter action, Jun 16, 2026.